https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-primary-sclerosing-cholangitis-likelihood-of-approval/
Hymecromoneis under clinical development by Halo Biosciences and currently in Phase II for Primary Sclerosing Cholangitis.
sclerosing cholangitishymecromonehalobiosciencesprimary
https://www.pharmaceutical-technology.com/data-insights/hymecromone-halo-biosciences-interstitial-lung-diseases-diffuse-parenchymal-lung-disease-likelihood-of-approval/
Hymecromoneis under clinical development by Halo Biosciences and currently in Phase II for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease).
interstitial lung diseaseshymecromonehalobiosciencesdiffuse